L aquinimod is an oral quinoline-3-carboxamide small molecule selected for its efficacy and safety from a pool of 60 quinoline-3-carboxamide derivatives of the parent compound, roquinimex, a drug previously evaluated in phase 2 trials of treatment for multiple sclerosis but withdrawn because of safety concerns. 1 Preclinical studies have shown that laquinimod reduces inflammatory cell infiltrates in the central nervous system, decreases demyelination, and prevents axonal loss. 2 It is currently in clinical development for the treatment of multiple sclerosis. [3] [4] [5] [6] [7] A 36-week, double-blind, placebo-controlled, phase 2 clinical trial showed a significant reduction in the primary end point, the cumulative number of gadolinium-enhancing lesions on magnetic resonance imaging (MRI), and also reductions in secondary MRI end points for patients receiving 0.6 mg of laquinimod, as compared with those receiving placebo. 3 Here we report results from the Assessment of Oral Laquinimod in Preventing Progression in Multiple Sclerosis (ALLEGRO) trial, a 24-month, double-blind, randomized, placebo-controlled, phase 3 study that was designed to evaluate the safety, efficacy, and tolerability of oral laquinimod at a dose of 0.6 mg administered once daily in patients with relapsing-remitting multiple sclerosis.
ME THODS

STUDY OVERSIGHT
The steering committee, in collaboration with the sponsor, Teva Pharmaceutical Industries, designed and monitored the study. The data and safety monitoring committee periodically reviewed the safety and efficacy data. The committee members are listed in the Supplementary Appendix, available with the full text of this article at NEJM.org. The data were collected and analyzed by the sponsor. All authors signed confidentiality agreements with the sponsor, had full access to the data, and vouch for the completeness and accuracy of the data analyses and interpretation. An independent medicalwriting-services agency, paid by the sponsor, wrote the first draft of the Methods and Results sections of this article, the first author wrote the first draft of the introduction and the Discussion section, and all authors reviewed the first and subsequent drafts of the manuscript. All the authors made the decision to submit the manuscript for publication. The study was conducted according to the protocol, which is available at NEJM.org.
PATIENTS
Patients were recruited from 139 sites in 24 countries (see the Supplementary Appendix for enrollment data by country). Recruitment was initiated in November 2007 and lasted 1 year. Eligibility criteria included a diagnosis of multiple sclerosis (according to the 2005 revised McDonald criteria 8 ) with a relapsing-remitting course, an age of 18 to 55 years, a score of no more than 5.5 on the Kurtzke Expanded Disability Status Scale (EDSS, which ranges from 0 to 10, with higher scores indicating more severe disability), 9 and a disease duration of at least 6 months before screening. Patients who had not received previous treatment or who had received disease-modifying agents were eligible if they had had one or more documented relapses in the 12 months before screening, two or more documented relapses in the 24 months before screening, or one documented relapse between 12 and 24 months before screening with at least one gadolinium-enhancing lesion in the previous year.
Patients were excluded if they had progressive forms of multiple sclerosis, an onset of relapse or receipt of any glucocorticoid treatment between screening and the baseline visit, or clinically significant or unstable medical or surgical conditions that would preclude safe and complete participation in the study. Additional exclusion criteria were use of investigative drugs or immunosuppressive agents (including mitoxantrone) within 6 months before screening; use of glatiramer acetate, any interferon, or intravenous immune globulin within 2 months before screening; use of glucocorticoids for at least 30 days within 2 months before screening; any previous use of natalizumab, cladribine, or laquinimod; and use of inhibitors of CYP3A4 within 2 weeks before the baseline visit.
As part of informed consent, the patients were informed of the available treatments. They provided written informed consent before participating in any study procedure, and they were asked to sign an additional informed-consent form after a relapse or confirmed disability progression (as measured by an increase of 2.0 or more points on the EDSS that was sustained for 3 months). The protocol was approved by all local institutional review boards before initiation of the study.
STUDY DESIGN
Patients were randomly assigned in a 1:1 ratio to receive an oral laquinimod capsule at a dose of 0.6 mg once daily or a matching placebo capsule. The randomization list, stratified according to study center, was computer-generated by the statistical data management department of the sponsor. Patients and investigators were unaware of the study assignments. Patients underwent 12 scheduled assessments at the study sites during the double-blind phase of the study: at screening, at baseline, and at months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24. EDSS scores were assessed every 3 months. Multiple Sclerosis Functional Composite (MSFC) scores were assessed every 6 months. The MSFC score is the average of the scores on the 9-hole peg test, the timed 25-ft walk, and the paced auditory serial-addition test with a 3-second interval between stimuli, with each score converted to a z score; higher scores reflect improvement. 10 MRI was performed annually in all patients.
Patients who discontinued the study during the double-blind phase underwent a final assessment at the time of discontinuation, with no further evaluation, except for those who discontinued the study owing to adverse events. Patients completing the 24-month study were given the opportunity to join an open-label study extension.
STUDY PROCEDURES AND END POINTS
Efficacy Measures
Neurologic evaluations, including safety assessments, were performed at screening, at baseline, and every 3 months until month 24. Neurologic assessments and general medical evaluations were conducted by two neurologists in order to minimize the possibility of unblinding: an examining neurologist with special training and certification (www.neurostatus.net) assessed neurologic condition, and the treating neurologist determined, on the basis of the EDSS score, whether a patient had a relapse.
The primary end point was the number of confirmed relapses during the double-blind study period. A relapse was defined as the appearance of one or more new neurologic abnormalities or the reappearance of one or more previously observed neurologic abnormalities lasting for at least 48 hours and occurring after an improved neurologic state for at least 30 days. An event was counted as a relapse if the patient's symptoms were accompanied by objective neurologic changes as indicated by at least one of the following: an increase of at least 0.5 points in the EDSS score, an increase of one grade in two or more of the seven functional systems that are graded in the EDSS (pyramidal, cerebellar, brain stem, sensory, bowel and bladder, visual, and cerebral), 9 or an increase of two grades in one functional system. The standard treatment of relapses was intravenous administration of methylprednisolone at a dose of 1 g per day for up to 5 consecutive days. Decisions regarding both hospitalization and treatment with glucocorticoids were made at the discretion of the treating neurologist, who was unaware of the study-group assignment.
Secondary end points were disability progression as measured by scores on the EDSS 9 and the MSFC. 10 Confirmed disability progression was defined as an increase in the EDSS score of at least 1.0 point from baseline if the baseline score was between 0 and 5.0 or an increase of at least 0.5 points if the baseline score was 5.5. To confirm disability progression, these increases had to be sustained for at least 3 months. Additional predefined disability end points are listed in the Supplementary Appendix.
For the MSFC, the measure was the total z score at 24 months, and the analysis included the scores of all patients who completed the double-blind phase or discontinued the study after the 12-month visit. Additional information on the MSFC is available in the Supplementary Appendix.
Secondary MRI end points were the cumulative number of gadolinium-enhancing lesions at 12 and 24 months (i.e., the sum of all gadoliniumenhancing lesions on scans at 12 months plus all gadolinium-enhancing lesions on scans at 24 months) and the cumulative number of new or enlarged lesions on T 2 -weighted images (>50% increase from the previous scan) at 12 * Plus-minus values are means ±SD. There were no significant differences between the two groups in clinical or demographic characteristics. MS denotes multiple sclerosis. † Scores on the Expanded Disability Status Scale (EDSS) range from 0 to 10, with higher scores indicating greater disability. ‡ Patients may have received more than one disease-modifying treatment before enrollment in the study. § For specific interferons, the numbers of patients are as follows: interferon beta-1b, 76 patients in the laquinimod group and 82 in the placebo group; interferon beta-1a, 133 and 123, respectively; and interferon, 0 and 3. ¶ Other disease-modifying treatments included antineoplastic agents (17 patients in the laquinimod group and 14 in the placebo group), immune globulin or immune serum (5 and 4, respectively), and immunosuppressive agents (13 and 21).
Safety and Adverse Events
Safety assessments included measurement of vital signs and weight, physical examination, electrocardiography, clinical laboratory tests, and recording of adverse events. Adverse-event analysis was based on the percentage of patients who discontinued the study and the percentage of patients who discontinued the study owing to adverse events.
STATISTICAL ANALYSIS
We estimated that a sample of 1000 patients (500 per study group) would provide 90% power to detect a significant change in the annualized relapse rate, assuming an expected annualized relapse rate of 0.65 among untreated patients, a 25% or greater reduction in the annualized relapse rate with laquinimod as compared with placebo, and a 20% rate of withdrawal from the study over a period of 24 months. Clinical and demographic characteristics and safety variables for all patients who underwent randomization were summarized with the use of descriptive statistics. Time to withdrawal was evaluated on the basis of Kaplan-Meier curves. Using Poisson regression with the study group as a covariate, we calculated the annualized relapse rate for the intention-to-treat cohort as the total number of confirmed relapses for all patients in each group, divided by the total patientyears in that group. In addition to the study group, we included as covariates the EDSS score at baseline, the log of the sum of 1 plus the number of relapses that occurred in the previous 2 years, and the country or geographic region.
To control for a type 1 error, the secondary end points were analyzed only after a significant effect was found for the primary end point. Likewise, the study's overall type 1 error was further controlled in the analysis of the secondary end points by application of the following gatekeeping approach: the cumulative number of new or enlarged lesions on T 2 -weighted images and the cumulative number of gadolinium-enhancing lesions at 12 months and at 24 months were tested simultaneously and the between-group difference for both end points had to be significant at an alpha level of 0.05, or the difference for one of the two end points had to be significant at an alpha level of 0.025, if the difference for the other end point was not significant at the 0.05 level. If the above condition was met, we proceeded to the analysis of the end point for confirmed disability progression; if this end point was significant at the 0.05 level, the analysis was performed for the total MSFC z scores. Additional methodologic details for the statistical analyses are included in the Statistical Analysis Plan in the Supplementary Appendix.
R E SULT S
STUDY POPULATION
Of the 1106 patients who underwent randomization, 550 were assigned to the laquinimod group and 556 to the placebo group. A total of 437 patients (79.5%) in the laquinimod group and 427 (76.8%) in the placebo group completed the 24-month study treatment. * Plus-minus values are means ±SE. IV denotes intravenous. † The P value was calculated with the use of a quasi-likelihood (overdispersed) Poisson regression analysis, with adjustment for EDSS score at baseline, log of the sum of 1 plus the number of relapses in the previous 2 years, and country or geographic region. ‡ The P value was calculated with the use of a logistic-regression analysis, with adjustment for baseline EDSS score, natural log of the sum of 1 plus the number of relapses in the previous 2 years, and country or geographic region. § The P value was calculated with the use of a Cox model regression analysis, with adjustment for baseline EDSS score, log of the sum of 1 plus the number of relapses in the previous 2 years, and country or geographic region. ¶ The Multiple Sclerosis Functional Composite (MSFC) is the average of scores on the 9-hole peg test, the timed 25-ft walk, and the paced auditory serial-addition test with a 3-second interval between stimuli, with each converted to a z score; higher scores reflect improvement. ‖ The P value was calculated with the use of an analysis of covariance, with adjustment for baseline MSFC score as a 1-degree-of-freedom covariate and baseline EDSS score, log of the sum of 1 plus the number of relapses in the previous 2 years, and country or geographic region as covariates. ** The P value was calculated with the use of a negative binomial regression model, with adjustment for number of gadolinium-enhancing lesions at baseline and country or geographic region and with an offset to adjust for absence of exposure to study treatment owing to early discontinuation. † † The P value was calculated with the use of analysis of covariance, with adjustment for number of gadolinium-enhancing lesions at baseline and the country or geographic region. 13.7% discontinued the study during the first year (12.0% in the laquinimod group and 15.2% in the placebo group), and an additional 8.2% discontinued the study during the second year (8.5% and 7.9%, respectively). Reasons for discontinuation of the study are shown in Figure 1 in the Supplementary Appendix. The most common reasons for discontinuation were the patient's decision not to sign the additional informed-consent form and withdrawal of consent after one relapse (8.0% of patients in the laquinimod group and 10.8% in the placebo group). The clinical and demographic characteristics of the study groups at baseline were well balanced (Table 1) .
RELAPSE END POINTS
The mean (±SD) annualized relapse rate during the 24-month treatment period (primary outcome) was significantly reduced in the laquinimod group as compared with the placebo group (0.30±0.02 vs. 0.39±0.03, P = 0.002) ( Table 2 ). In exploratory analyses that were prespecified in the protocol, the percentage of patients who were relapse-free was 62.9% in the laquinimod group (346 of 550 patients) and 52.2% in the placebo group (290 of 556, P<0.001); the time to the first relapse during the study was longer for patients receiving laquinimod than for those receiving placebo, and the risk of relapse was significantly reduced with laquinimod (hazard ratio, 0.72; 95% confidence interval, 0.59 to 0.87; P<0.001).
In an additional prespecified exploratory analysis, the annualized rate of relapse requiring hospitalization or intravenous treatment with glucocorticoids, according to the treating neurologist's decision, was significantly lower among patients receiving laquinimod as compared with those receiving placebo (0.24 vs. 0.33, P<0.001).
DISABILITY END POINTS
The risk of disability progression as assessed by an increase in EDSS scores that was sustained for 3 months (secondary outcome) was significantly decreased for patients receiving laquinimod, as compared with those receiving placebo (11.1% vs. 15.7%; hazard ratio, 0.64; P = 0.01) (Fig. 1B) . This observation was reinforced by two findings from additional analyses: the risk of confirmed progression was significantly reduced with the use of the more stringent approach, which required the persistence of the change in the EDSS score at the last available assessment (hazard ratio with laquinimod, 0.66; P = 0.04), and the actual proportion of patients with confirmed disability progression at the last assessment was lower in the laquinimod group than in the placebo group (9.8% [54 of 550 patients] vs. 14.0% [78 of 556], P = 0.04). The mean EDSS scores at the last assessment were 2.68 and 2.79 in the laquinimod and placebo groups, respectively (P = 0.05). In an analysis that was not prespecified in the protocol but was designed before the initiation of data analyses, there was a decrease in the risk of confirmed disability progression at 6 months with laquinimod (hazard ratio, 0.52; P = 0.002). There was little overall change in the MSFC scores from baseline to 24 months (secondary outcome), and the adjusted mean total MSFC z score at 24 months did not differ significantly between the laquinimod group and the placebo group (0.06 and 0.04, respectively; P = 0.59).
MRI END POINTS
Laquinimod reduced the mean cumulative number of gadolinium-enhancing lesions (secondary outcome), as compared with placebo (rate ratio, 0.63; P<0.001) (Fig. 1C) . The mean cumulative number of new or enlarged lesions on T 2 -weighted images at 12 and 24 months (secondary outcome) was also reduced in the laquinimod group (rate ratio, 0.70; P<0.001). In a prespecified exploratory analysis, patients receiving laquinimod had a lower percentage of brain-volume loss from baseline to 24 months, as compared with patients receiving placebo (adjusted mean, −0.87% vs. −1.30%; mean difference, 0.43 percentage points; P<0.001) (see the Supplementary Appendix).
SAFETY PROFILE AND ADVERSE EVENTS
No deaths occurred in the laquinimod group, and three deaths occurred in the placebo group (from injury, suicide, and complications of pneumonia). A total of 122 serious adverse events were reported in 11.1% of patients receiving laquinimod (61 of 550), and 90 were reported in 9.5% of those receiving placebo (53 of 556); events occurring in at least 2 patients in the laquinimod group and those occurring at a higher frequency in the laquinimod group than in the placebo group are shown in Table  3 . A higher incidence of appendicitis was reported in the laquinimod group than in the placebo group (5 cases vs. 1). In all cases, an appendectomy was performed, without additional complications, and the patients continued with the study treatment.
There were 14 cases of neoplasms (8 in the laquinimod group and 6 in the placebo group) with a large variation in the type of cancer. There were 3309 adverse events in the laquinimod group and 2965 in the placebo group, with 87% and 81% of patients, respectively, reporting * Serious adverse events reported here are those that occurred in two or more patients in the laquinimod group or occurred more often in the laquinimod group than in the placebo group. Adverse events reported here are those that occurred in 5% or more of all patients or that occurred more often in the laquinimod group than in the placebo group. ALT denotes alanine aminotransferase, and ULN upper limit of the normal range. † One patient had received partial treatment for breast cancer before enrollment in the study; metastases were revealed on the same side. ‡ One patient had a history of long-standing esophageal pain before enrollment in the study, which had been attributed to depression. § A retrospective assessment showed the tumor on the baseline MRI scan. ¶ Data shown are all ALT elevations that were reported as adverse events. ‖ Data shown are all ALT elevations in the specified categories, which were not necessarily reported as adverse events.
The analysis included only patients who had ALT levels below the upper limit of the normal range at baseline. ** Six patients (1.1%) receiving laquinimod and one receiving placebo (0.1%) discontinued the study because of the ALT elevation. † † The protocol mandated discontinuation of the study if this elevation persisted for 2 weeks; two patients (0.4%) receiving laquinimod and one (0.2%) receiving placebo discontinued the study. ‡ ‡ For this elevation, the protocol mandated immediate discontinuation of the study; three patients (0.6%) receiving laquinimod and four (0.8%) receiving placebo discontinued the study.
The one or more events. Adverse events that occurred in at least 5% of all patients and those that occurred at a higher rate in the laquinimod group than in the placebo group are listed in . These adverse events were rarely associated with discontinuation of the study (3% and 1% of the laquinimod and placebo groups, respectively).
More patients in the laquinimod group than in the placebo group had alanine aminotransferase levels that were greater than 3 times the upper limit of the normal range but less than or equal to 5 times the upper limit (18 patients [3.6%] vs. 2 [0.4%]). In contrast, alanine aminotransferase levels that were greater than 5 times the upper limit of the normal range occurred equally often in the two groups (in 6 patients in each group) and led to equal rates of discontinuation. Elevations to values that were up to or equal to 5 times the upper limit of the normal range usually occurred within the first 6 months, and in all cases, they were reversible either without discontinuation of the study drug or within 2 months after discontinuation. There were no cases of liver failure and no cases of concomitant elevations of bilirubin levels or coagulation values (Hy's law, which states that an elevation of liver aminotransferases along with an elevation of bilirubin is predictive of liver failure). 12 Elevated levels of alanine aminotransferase (from 3 to less than 5 times the upper limit of the normal range) led to discontinuation in 6 patients receiving laquinimod and in 1 receiving placebo.
DISCUSSION
The ALLEGRO study showed that, as compared with placebo, laquinimod significantly but modestly reduced the annualized rate of relapse of multiple sclerosis in a manner consistent with its suppression of inflammatory disease activity, as measured by MRI. Laquinimod was also associated with a significant reduction in the risk of confirmed progression of disability. We did not detect significant between-group differences in the MSFC scores. The significant reduction in the exploratory end point of the percent change in brain volume, as measured by MRI, in this study is an interesting corollary to the effect on disability progression.
Elevated levels of liver enzymes occurred 2 times more frequently in the laquinimod group. These elevations were transient and were not associated with clinical, imaging, or laboratory signs of liver failure. Abdominal pain occurred more frequently in the patients who received laquinimod than in those who received placebo; however, it was rarely a reason for discontinuation of the study treatment. It is worth noting that the safety concerns previously seen with roquinimex, 13 such as serositis, cardiovascular events, and thrombosis, did not emerge as signals in the current study. Although long-term studies are needed to adequately assess the risk of infections and cancers, we did not observe increased rates of these serious adverse events. An open-label extension of the study, involving 844 of the 864 patients who completed the study, is ongoing. The data and safety monitoring committee has not reported any new safety signals so far in this extension study.
In conclusion, we found that laquinimod, as compared with placebo, reduced the rate of relapse and slowed the progression of disability in patients with relapsing-remitting multiple sclerosis.
